Shares plunge 36% after nine-year DMD drug trial misses endpoint. Q3 revenue beats but clinical failure dominates sentiment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback